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Abstract
Background: The sentinel lymph node biopsy (SLN) is a basic staging method in all primary cutaneous melanomas
≥pT1b. The standard technique is a triple technique consisting of preoperative lymphoscintigraphy, intraoperative
blue-dye lymphography, and gamma-probe assessment. We performed the analysis of long-term results in a very
large one-institution series of cutaneous melanoma patients.
Methods: We have analyzed treatment results of a group of 1764 consecutive patients with cutaneous melanoma,
who underwent SLN biopsy between 1997 and 2008 in one tertiary center. Additionally, we have analyzed the
outcomes of a group of 473 patients with positive SLN biopsy undergoing completion lymph node dissection
(CLND). Median follow-up time was 5.3 years.
Results: Metastases to SLN (SLN+) were found in 19.9 %. Eight-year overall survival (OS) rate in the entire group was
73.5 %, 80 % without SLN metastases (SLN−) and 50 % in group with SLN+ (p < 0.001). Independent prognostic factors
for OS were as follows: presence of metastases to SLN, primary tumor ulceration, and higher mitotic index (>5/mm2) of
primary tumor. The nodal recurrences in the biopsied lymphatic basin were 5.4 %. The metastases to non-sentinel
lymph nodes (NSLN found in 27 % of patients with SLN+) correlated (on multivariable logistic regression analysis) with
primary tumor thickness >4 mm, SLN metastatic deposit size >1 mm, and extracapsular involvement of SLN. In an
additionally analyzed SLN+ group, the NSLN involvement was related to poorer prognosis (8-year OS rate NSLN− vs
NSLN+: 59.6 vs. 34.7 %, respectively). The independent prognostic factors for OS in the SLN+ group were a higher
Breslow thickness and ulceration of primary tumor, metastases to more than 1 lymph nodes.
Conclusions: The long-term results confirm crucial prognostic significance of SLN biopsy in cutaneous melanoma. We
identified factors related to NSLN involvement, which in the future may limit indications for CLND.
Keywords: Melanoma, Sentinel lymph node biopsy, Mitotic rate, Non-sentinel lymph node, Prognosis, Tumor burden
* Correspondence: mzdzienicki@coi.waw.pl
The preliminary results of this study were presented as oral presentation
during Congress of European Society of Surgical Oncology 2014 in Liverpool
UK.
†Equal contributors
1Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
Roentgena 5, 02-781 Warsaw, Poland
Full list of author information is available at the end of the article
WORLD JOURNAL OF 
SURGICAL ONCOLOGY
© 2015 Rutkowski et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rutkowski et al. World Journal of Surgical Oncology  (2015) 13:299 
DOI 10.1186/s12957-015-0701-8
Background
Several studies have already proven that sentinel lymph
node (SLN) biopsy offers several benefits in the course
of melanoma patient management: excellent prognostic
information, better staging, avoiding unnecessary elective
lymph node dissection (LND), facilitation of therapeutic
lymphadenectomy, homogeneity of patient populations in
clinical trials on adjuvant therapy, patients’ increased
sense of safety, and accuracy of care [1–4].
SLN biopsy developed in the early 1990s [5], in 1999 was
declared by the World Health Organization as a standard
of care in the management of melanoma patients without
evidence of metastases, and thereafter the American Joint
Committee on Cancer (AJCC) incorporated SLN biopsy as
a microstaging procedure in the TNM-staging system [6,
7]. In 2012, the American Society of Surgical Oncology
and Society of Surgical Oncology confirmed that SLN bi-
opsy is recommended in all primary melanoma patients
with a Breslow thickness >1 mm and also in those patients
with thinner melanomas but at the same time with other
negative pathological features. Finally, the definitive ana-
lysis from the Multicenter Selective Lymphadenectomy
Trial-1 (MSLT-1), which randomized patients into those
who underwent SLN biopsy and others who did not, was
published in 2014 [8].
Currently, we can present the long-term outcomes of
SLN biopsy used in routine practice based on a very
large one-institution series of cutaneous melanoma pa-
tients, and we can focus on some issues reflecting the
relationship between pathological characteristics of the
tumor and SLN with patients’ survival.
We performed the analysis of long-term results of
SLN biopsy, and additionally, in the subgroup of pa-
tients, we analyzed the impact of new possible prognos-
tic factors on patient outcomes, including mitotic index
of the primary tumor (introduced to the AJCC staging
system in 2009) and features of SLN metastases.
Methods
Patients
We analyzed the outcomes of 1764 consecutive patients
with histologically confirmed primary cutaneous melanoma
in clinical stages I–II according to the AJCC 2010 classifica-
tion [9], who underwent sentinel node biopsy at the De-
partment of Soft Tissue/Bone Sarcoma and Melanoma at
the Maria Sklodowska-Curie Memorial Cancer Centre and
Institute of Oncology, Warsaw, Poland (CCIO), between
1998 and 2008 (cohort 1) (Table 1). In all patients, the triple
technique was used consisting of preoperative lymphoscin-
tigraphy, blue-dye injection, and intraoperative lymphoscin-
tigraphy with a hand-held gamma-detecting probe. We
have already presented the detailed technique of SNB and
of the pathologic examination of SLNs in our previous pub-
lications [1]. The false-negative cases were defined as a
nodal recurrence after an initially negative SLN biopsy in
the biopsied basin without preceding local or in-transit
recurrences. In the case of positive SLN, all but three
patients underwent completion lymph node dissection
(CLND). The margin of excision of all the primaries was
≥1 cm. Each patient provided written informed consent.
The study was approved by the local Bio-Ethics Committee
according to Good Clinical Practice Guidelines.
All patients undergoing SLN biopsy met the following
criteria:
– Primary focus cutaneous melanoma after excisional
biopsy with Breslow thickness ≥0.75 mm or
ulcerated or Clark level ≥IV (all histological
diagnoses were confirmed in the Department of
Pathology, CCIO)
– Clinically non-palpable regional lymph nodes
– Absence of distant metastases (confirmed routinely
by physical examination, chest X-ray, and ultrason-
ography of the abdominal cavity)
– Feasibility for general anesthesia
The patients had not undergone any other preliminary
selection. Only patients who met with all the conditions
listed above were enrolled in the study.
The clinico-pathological stage of the melanoma patients
was determined by pathological evaluation of the primary
lesion and of the dissected lymph nodes, as well as by
physical examination and routine imaging examinations
(chest X-ray, ultrasonography of the abdominal cavity, and
computed tomography imaging, if necessary).
Patient characteristics of the cohort 1 are summarized
in Table 1. In an additional 805 cases, two pathologists
reviewed mitotic index per mm2. All patients had con-
firmed primary melanoma. Radical lymph node dissec-
tions were performed according to the technique
described by Karakoussis [10]. For ilio-inguinal lymph-
adenectomy, we routinely excised the superficial and
deep levels below the inguinal ligament to the level of
the aortic bifurcation combined with obturatory lymph
node dissection. Two hundred and one patients received
interferon-α2b as adjuvant treatment in accordance with
the European Organisation for Research and Treatment
of Cancer (EORTC) 18952 trial (without significant in-
fluence on overall survival data) [11, 12].
Additionally, we analyzed all consecutive patients
(N = 473) who underwent radical CLND at the Depart-
ment of Soft Tissue/Bone Sarcoma and Melanoma at
the CCIO between May 1995 and December 2008 due
to positive SLN biopsy (cohort 2) independent of the
SLN biopsy technique used (Table 2).
All patients were followed carefully with a median
follow-up time of 4.9 years (range: 6–151 months; co-
hort 1) and 5.4 years (range: 6–174 months; cohort 2).
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Postoperative follow-up consisted of physical examination
and routine imaging investigations (chest X-ray and ultra-
sound examination of the abdominal cavity; chest/abdom-
inal computed tomography examination was done for
follow-up in SLN-positive or symptomatic patients). Rou-
tinely, surveillance was recommended every 3 months for
the first 2 years, every 4 months in year 3, every 6 months
for years 4–5, and thereafter annually.
Pathological examination
The SLNs were evaluated by serial sectioning, and H&E
staining was performed first. If this was negative, other
slides were stained with immunohistochemical methods.
The amount of SLN tumor burden was measured ac-
cording to the Rotterdam criteria [13], which consist
of the measure of the maximum diameter (in any direction)
of the largest lesion on a slide (N = 363). All positive slides
were examined, and this process of measuring the largest le-
sion was repeated. The largest value overall (which is the lar-
gest diameter measured anywhere on one slide in one
patient) has been defined as the amount of SLN tumor bur-
den (in mm). If a patient had multiple positive SLNs, the lar-
gest maximum diameter of any of the SLNs was the largest
overall and thus the amount of SN tumor burden for this
patient. Categories were made for SLN tumor burden as fol-
lows: <0.1 (sub-micrometastases), 0.1–1.0, and >1.0 mm.
The location of the metastases was also recorded, according
to the Dewar criteria for the microanatomic location of the
metastasis [14] (N= 347). This was either subcapsular, par-
enchymal, combined, multifocal, or extensive.
Table 1 Patient characteristics of all patients undergoing SLN biopsy (cohort 1) and overall survival (OS)
Parameter Value N (%) 5-year OS 95 % CI 8-year OS 95 % CI p value log-rank test
Płeć Female 1021 (57.9 %) 84.8 (82.2–87.4) 78.6 (74.9–82.5) 0.001
Male 743 (42.1 %) 72.3 (68.5–76.4) 66.6 (61.6–72.0)
Tumor type NM 695 (39.4 %) 74.0 (70.2–78.0) 67.5 (62.8–72.5) 0.0001
SSM 516 (29.25 %) 87.1 (83.7–90.6) 82.2 (77.0–87.9)
ALM 44 (2.49 %) 65.0 (51.0–82.8) 65.0 (51.0–82.8)
LMM 122 (6.92 %) 84.3 (76.6–92.7) 77.5 (66.7–90.1)
Other 9 (0.51 %) 83.3 (58.3–100.0) 83.3 (58.3–100.0)
NA 378 (21.43 %) 80.0 (75.0–85.4) 73.2 (66.1–81.0)
Clark level 2 253 (14.34 %) 90.7 (86.3–95.3) 84.2 (77.0–92.2) 0.001
3 818 (46.37 %) 86.1 (83.3–89.0) 78.8 (74.5–83.4)
4 490 (27.78 %) 68.7 (63.8–73.9) 65.4 (60.1–71.3)
5 110 (6.24 %) 54.7 (44.9–66.6) 47.2 (36.2–61.5)
NA 93 (5.27 %) 78.9 (69.7–89.3) 78.9 (69.7–89.3)
Ulceration of primary tumor 0 931 (52.78 %) 90.4 (88.1–92.7) 84.8 (81.0–88.8) 0.001
1 713 (40.59 %) 65.7 (61.7–70.0) 58.9 (54.1–64.3)
NA 115 (6.63 %) 79.5 (70.9–89.1) 76.5 (66.8–87.7)
Extracapsular involvement of
sentinel node metastases
0 321 62.4 (56.7–68.7) 54.2 (47.5–61.7) 0
1 96 33.8 (25.1–45.6) 27.0 (18.6–39.2)
NA 1341 88.6 (86.4–90.7) 84.2 (81.0–87.4)
Mitotic index <1/mm2 123 (15.28 %) 92.9 (86.0–100.0) 92.9 (86.0–100.0) 0.002
1/mm2 142 (17.64 %) 89.9 (81.2–99.5) 89.9 (81.2–99.5)
2–5/mm2 262 (32.55 %) 88.3 (83.3–93.6) 84.7 (78.0–92.0)
>5/mm2 278 (34.53 %) 63.1 (56.4–70.7) 61.6 (54.5–69.7)
Breslow thickness ≤1 mm 343 (19.44 %) 94.2 (91.0–97.4) 88.7 (82.7–95.2) 0.001
1.01–2.00 mm 449 (25.45 %) 91.5 (88.5–94.7) 87.8 (83.1–92.8)
2.01–4.00 mm 519 (29.42 %) 75.6 (71.1–80.3) 68.0 (61.8–74.7)
>4 mm 398 (22.56 %) 60.8 (55.5–66.6) 54.4 (48.4–61.0)
NA 55 (3.12 %) 75.4 (62.8–90.4) 70.9 (57.1–88.1)
Sentinel node metastases No 1413 (80.10 %) 86.3 (84.1–88.5) 80.4 (77.1–83.9) 0.001
Yes 351 (19.9 %) 55.6 (50.1–61.9) 49.8 (43.7–56.8)
All patients 1764 79.5 (77.2–81.8) 73.5 (70.5–76.7)
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Table 2 Patient characteristics of patients undergoing completion lymph node dissection due to positive SLN biopsy (cohort 2) and
overall survival (OS) N = 473
Parameter Value N (%) 5-year OS 95 % CI 8-year OS 95 % CI p value log-rank test
Sex Female 235 (49.6 %) 63.0 (56.4–70.5) 59.1 (52.1–67.0) 0.032
Male 238 (50.4 %) 51.2 (44.2–59.4) 44.8 (37.3–53.9)
Tumor type NM 264 57.2 (50.6–64.6) 51.0 (44.1–59.1) 0.006
SSM 96 63.8 (53.7–75.8) 61.1 (50.5–74.1)
ALM 15 20.0 (6.3–63.8) 20.0 (6.3–63.8)
LMM 16 46.1 (25.2–84.3) 46.1 (25.2–84.3)
Other 2 100.0 (100.0–100.0) 100.0 (100.0–100.0)
NA 80 58.7 (47.4–72.7) 54.0 (42.3–68.9)
Clark level II 29 49.4 (31.7–77.1) 43.2 (25.8–72.4) 0.068
III 154 69.8 (62.2–78.4) 61.4 (52.1–72.4)
IV 206 51.9 (44.2–60.9) 50.8 (43.1–59.9)
V 64 46.3 (34.8–61.5) 39.6 (28.3–55.3)
NA 20 63.6 (43.8–92.3) 56.5 (36.5–87.6)
Presence of ulceration of primary tumor No 143 73.2 (65.0–82.3) 68.4 (59.5–78.7) 0.000
Yes 293 49.0 (42.7–56.1) 43.8 (37.3–51.4)
NA 37 60.9 (45.7–81.4) 57.1 (41.7–78.3)
Extracapsular involvement of
sentinel node metastases
No 363 58.5 (53.0–64.7) 52.7 (46.8–59.4) 0.008
Yes 98 40.1 (27.8–57.8) 37.2 (25.1–55.2)
NA 12 68.9 (54.4–87.4) 68.9 (54.4–87.4)
Breslow thickness ≤1 mm 29 81.9 (67.3–99.8) 70.6 (53.0–94.0) 0.000
1.01–2.00 mm 56 75.6 (63.8–89.5) 75.6 (63.8–89.5)
2.01–4.00 mm 164 61.9 (53.4–71.8) 57.6 (48.1–68.9)
>4 mm 199 44.3 (37.2–52.8) 39.8 (32.6–48.6)
NA 25 60.8 (40.8–90.5) 43.4 (23.5–80.3)
Size of metastasis in sentinel node <0.1 mm 10 87.5 (67.3–100.0) 87.5 (67.3–100.0) 0.009
0.1–1.0 mm 107 63.0 (53.6–74.2) 57.7 (47.0–71.0)
>10.0 mm 246 47.3 (40.3–55.6) 41.6 (34.4–50.4)
NA 110 56.8 (45.3–71.2) 48.4 (36.2–64.7)
Localization of metastasis in sentinel node Subcapsular 25 79.4 (63.1–100.0) 79.4 (63.1–100.0) 0.060
Combined 165 57.8 (49.7–67.1) 51.5 (42.4–62.5)
Parenchymal 67 52.2 (40.6–67.2) 44.0 (32.0–60.6)
Multifocal 15 55.0 (32.2–93.8) 55.0 (32.2–93.8)
Extensive 75 40.8 (29.8–55.9) 38.5 (27.6–53.8)
NA 126 66.8 (57.5–77.6) 61.7 (51.8–73.5)
Presence of non-sentinel node metastases No 341 63.9 (58.2–70.2) 59.6 (53.5–66.3) 0.000
Yes 132 41.4 (32.9–52.2) 34.7 (25.9–46.6)
LND basin Axillary 261 56.4 (49.8–64.0) 49.5 (42.1–58.1) 0.316
Neck 3 50.0 (12.5–100.0) 50.0 (12.5–100.0)
Inguinal 174 63.0 (55.4–71.5) 59.0 (51.2–68.1)
Other 35 28.9 (14.3–58.6) 28.9 (14.3–58.6)
Number of metastatic nodes 1 259 66.3 (60.0–73.3) 62.7 (55.9–70.3) 0.000
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Statistical analyses
The statistical analysis was done using R 3.0.1 statistical soft-
ware (R Core Team (2013). R: A language and environment
for statistical computing. R Foundation for Statistical Com-
puting, Vienna, Austria. URL http://www.R-project.org/).
Packages: survival (Therneau T (2013). “A Package for
Survival Analysis in S”. R package version 2.37-4, URL:
http://CRAN.R-project.org/package=survival).
Logistic regression and survival analysis methods were
used in the analysis. Potential risk factors of positive
SLN (cohort 1) and metastases to non-sentinel lymph
nodes (NSLN) (cohort 2) were investigated using univar-
iate and multivariate logistic regression model. Variables
with p < 0.10 were included in the initial stage of multi-
variate model building. Backward variable selection was
then used to construct the final model.
The Kaplan-Meier estimates and Cox regression
model were used in survival analysis. Patient’s survival
was described using 5- and 8-year survival probability
(with 95 % confidence interval) and survival curve plots.
Overall survival (OS) time for the assessment of the
prognostic value of clinical and pathological parameters
was calculated from the date of primary tumor excision
to the date of the most recent follow-up (censored data)
or death. Clinical and pathological parameters are as fol-
lows: gender, primary tumor Breslow thickness (≤1.0 vs.
1.01–2.0 vs. 2.01–4.0 vs. >4.0 mm), presence of ulcer-
ation of primary lesion, primary tumor level of invasion
according to Clark (II, III, IV, V), primary tumor patho-
logical type (nodular melanoma [NM], superficial
spreading melanoma [SSM], acral lentiginous melanoma
[ALM], lentigo malignant melanoma [LMM], others),
mitotic index of primary tumor (<1/mm2, 1/mm2, 2–5/
mm2, >5/mm2; cohort 1 only), and presence of metasta-
ses to SLN (cohort 1 only), and additionally in cohort 2:
localization of lymphadenectomy (inguinal vs. axillary),
number of lymph nodes with metastases (1 vs. 2–3
vs. ≥4), presence of extracapsular invasion in involved
lymph nodes, presence of metastases to NSLN
(assessed after CLND), size of metastases to SLN ac-
cording to the Rotterdam criteria, and microanatomic
location of the metastasis in SLN (subcapsular, com-
bined, parenchymal, multifocal, extensive) were tested
as a factors affecting patients survival.
The multivariate Cox model was used to identify inde-
pendent risk factors affecting patients’ survival. Procedure
of final model building was the same as in case logistic re-
gression model. The differences were considered statisti-
cally significant if the p values were <0.05.
Results
Survival analysis (from the date of primary tumor
excision) in all patients undergoing SLN biopsy (cohort 1)
The patient characteristics and the results of an univariate
analysis of the impact of individual factors on overall sur-
vival are shown in (Table 1). The median Breslow thickness
of the entire group was 2.3 mm. In the analyzed subgroup
of 805 patients with known mitotic index of primary
tumor, we have observed the high correlation between in-
creasing Breslow thickness and higher mitotic rate (Spear-
man’s correlation coefficient 0.425, p value <0.001).
The median 5-year and 8-year OS rates were 79.5 %
(95 % confidence interval [CI]: 77.2–81.8 %) and 73.5 %
(95 % CI: 70.5–76.7 %), respectively, in the entire group
of patients who underwent SLN biopsy.
According to the multivariate analysis, we have identified
three of the most important factors negatively influencing
OS: mitotic index >5/mm2 (hazard ratio [HR] = 1.1) (Fig. 1),
presence of ulceration of primary tumor (HR = 4.1), and the
presence of metastases to SLN (HR = 2.2) (Fig. 2) (Table 2).
Factors influencing on the presence metastases to SLN
In 351 cases (19.9 %), we found positive SLNs (347 of
them underwent completion lymph node dissection
[CLND]). Based on the univariate logistic regression
model, we have found the following factors related to
presence of metastases to SLN: male gender (p = 0.002),
Clark level >II (p < 0.01), presence of ulceration of
Table 2 Patient characteristics of patients undergoing completion lymph node dissection due to positive SLN biopsy (cohort 2) and
overall survival (OS) N = 473 (Continued)
2–3 150 48.6 (40.0–59.0) 44.5 (35.7–55.3)
>3 50 38.2 (26.0–56.0) 24.3 (13.5–43.8)
NA 14 0.0 (63.3–100.0) 0.0 (63.3–100.0)
All patients 473 57.3 (52.3–62.7) 52.3 (47.0–58.1) 0.000
Fig. 1 Overall survival curves according to mitotic index of primary
tumor in all patients undergoing SLNB (cohort 1) (1, <1/mm2; 2, 1/
mm2; 3, 2–5/mm2; 4. >5/mm2)
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primary tumor (p < 0.001), and Breslow thickness of pri-
mary tumor >2 mm (p < 0.001). In multivariate analysis
(Table 3), male gender Clark level IV or V and ulceration
of the primary tumor were independently related to the
presence of metastases to SLN.
Moreover, in pT1 tumors (Breslow thickness ≤1.00 mm)
with known mitotic index (n = 139), we have not found any
metastases to SLNs in cases with MI < 1/mm2 (0/40); for 46
tumors with MI = 1/mm2, we detected four SLNs+ (8.7 %);
and for 53 tumors with MI > 1/mm2, we found metastases
in three SLNs (6 %) (Fig. 3).
The SLN biopsy failure rate (defined as nodal recur-
rences in the biopsied regional basin without simultan-
eous or previous local/in-transit recurrences) was 6.3 %
(90/1413 SLN negative or calculated as false-negative
rate 20 % 90/351 + 90). Median time to nodal relapses
after false-negative SLN biopsy was 16 months.
Analysis of factors influencing on outcomes in CLND
group /cohort 2/
The patient characteristics and factors in relation to
5-year and 8-year OS rates are shown in Table 4. Ac-
cording to the univariate analysis, the following fac-
tors had a negative impact on the overall survival of
patients after CLND: male gender, ALM primary
tumor type, higher primary tumor Breslow thickness
(>2 mm), ulceration of primary tumor, number of
lymph node with metastases >1 (Fig. 4), extracapsular
extension of nodal metastases (Fig. 5), the presence of
metastases to non-sentinel lymph nodes (NSLN)
(Fig. 6), the size of metastases to SLN according to
Rotterdam criteria ≥1.0 mm (Fig. 7), and with the
borderline significance other than subcapsular microa-
natomic location of the metastasis to SLN.
According to the multivariate analysis, we have con-
firmed and identified that in the CLND group the
most important factors negatively influencing OS are
as follows: features of primary tumor (higher Breslow
thickness >2.0 mm [HR = 1.01], presence of ulceration
[HR = 2.5], and ALM tumor type [p = 4.8]) and features of
nodal metastases (number of involved nodes >1 [HR =
2.05]) (Table 5).
Factors influencing on the presence of metastases to
non-sentinel lymph node (NSLN)
In 132 of 473 patients (27.9 %), we have identified add-
itional metastases in NSLSN afer CLND.
The presence of metastases to NSLN correlated ac-
cording to univariate and multivariate analyses (Table 6)
with extracapsular metastases to SLN (p < 0.001), pri-
mary tumor Breslow thickness >2 mm (p < 0.001), and
maximal diameter of metastases to SLN according to
Rotterdam analyzed as a continuous variable (p < 0.001).
Discussion
We have confirmed the importance of SLN biopsy as a
tool for accurate staging and prognosis assessment in
the routine practice of patients with cutaneous melan-
oma. The presence of metastases to SLN found in up to
20 % of patients [8, 15] is related to almost twice less
survival after 8 years from primary tumor excision as
compared to patients with SLN-negative tumors. The
randomized study MSLT-1 assessing prospectively the
value of SLN biopsy found SLN status, Breslow thick-
ness, ulceration presence, and localization of the primary
tumor on the trunk as the independent prognostic
factors related to death from melanoma in intermediate-
thickness tumors [8]. We also found SLN status and ul-
ceration of the primary tumor as independent prognostic
factors for OS in the entire group of patients undergoing
SLN biopsy. However, we have also demonstrated the in-
dependent negative value of high mitotic index of the
primary tumor in this group of patients (which corre-
lates with the tumor Breslow thickness). This newly
introduced criterion for melanoma staging and progno-
sis replaced Clark’s level of invasion for thin melano-
mas and is thought to be related with patients’
survival [9, 16]. We also found the inverse correlation
between primary tumor mitotic rate and OS, especially
pronounced for a mitotic index higher than 5/mm2. Our
results highlight the value of routine pathologic reporting
of the mitotic index of primary melanoma as it is an inde-
pendent prognostic factor for patients with localized
primary melanomas in clinical stages I and II undergoing
SLN biopsy and it is the first one-institution
Fig. 2 Overall survival curves according the presence of metastases
to SLN (0—no metastases, 1—metastases to SLN) in all patients
undergoing SLN biopsy (cohort 2)
Table 3 Multivariate analysis for overall survival in patients
undergoing SLN biopsy (cohort 1)
Parameter HR 95 % CI p value
Mitotic index 1.071 1.01–1.136 0.021
Ulceration 4.114 1.766–9.585 0.001
Presence of metastases in SLN 2.184 1.125–4.24 0.021
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comprehensive study including pathological review aiming
at the standardization of technique of mitotic rate
assessment.
The use of SLNB reliably identifies melanoma pa-
tients with nodal micrometastases, enabling clinicians
to identify patients with occult nodal metastases that
would otherwise take months or years to become
clinically palpable—it has been confirmed by the
MSLT-1 trial data that cumulative rates of nodal in-
volvement in patients undergoing SLN biopsy or not
are similar. Currently, the positive result of SLN bi-
opsy is a major manifestation of stage III melanomas.
The results of the current study confirmed our previ-
ous data, as well as data from the AJCC staging data-
base, demonstrating that in a group of patients with
micrometastases both primary tumor features as well
as nodal characteristics have independent prognostic
value for OS assessment [17, 18]. Our results indicate
also the heterogeneity of patients undergoing CLND
due to positive SLN, which is strictly related to tumor
load. The number of nodal metastases is still a very
powerful independent predictor of survival among all
patients with micrometastatic stage III disease, but
microanatomic features of SLN metastases should also
be taken into account when the patient’s prognosis is
discussed.
In view of the SLN positivity in only one of five
patients, some studies tried to predict SLN status in
patients undergoing SLN biopsy [19, 20]. Although we
did not analyze patients’ age as a prognostic factor [21]
in our database due to differently used cutoff values in
different databases and because we have focused on
pathological features of primary tumor, we have con-
firmed that the Clark level of invasion and ulceration of
primary tumor and additionally male gender correlated
independently with SLN positivity. The results of our
study underlines the position of ASCO and SSO, that in
very thin melanomas up to 1 mm according to Breslow,
the presence of a mitotic rate ≥1/mm2 can be an
Fig 3 Relationship between mitotic index of primary tumor and SLN positivity in pT1 group
Table 4 Multivariate model—factors related to metastases in
sentinel nodes
Variable OR ORL ORU p value
Sex (male) 1.392 1.075 1.801 0.012
Clark III 1.635 0.986 2.711 0.056
Clark IV 3.440 2.067 5.725 0.000
Clark V 6.034 3.262 11.161 0.000
Ulceration of primary tumor 2.586 1.981 3.376 0.000
Fig. 4 Overall survival curves according to number of lymph node
with metastases in group of patients with positive SLN biopsy after
CLND (cohort 2) (1–1, 2–2–3, 3 > 3)
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additional feature to propose to the patient to undergo
SLN biopsy [22, 23].
Our study also highlights the fact that although the
procedure of SLN biopsy may be quite accurate, it mis-
ses 20 % of positive nodes in patients with primary mel-
anoma (this false-negative rate is consistent with other
studies) [24].
The presence of metastases to NSLN is a highly
negative prognostic factor for patient survival ana-
lyzed recently by other authors [25–28], and they
found up to 30 % of SLN-positive cases after CLND
(27 % in our series). According to our analysis, the
positivity of NSLN is related to a 50 % higher chance
of death after 8 years as compared to patients with
metastases limited to SLN only. It may support the
hypothesis that SLN may be a physiological barrier
for melanoma spreading. It is one of the reasons for
prediction of the necessity to perform CLND after
positive SLN. After many attempts by different au-
thors, there is still no universal approach based on
morphologic criteria to not allow performing CLND
in selected SLN-positive cases. We have confirmed in
our group of patients that the Rotterdam criteria for
assessment of tumor burden in SLN give the prog-
nostic information, and this pathological factor is
closely associated with the presence of metastases to
additional NSLN after CLND, which has been sug-
gested previously [14, 29, 30]. A combination of pa-
tients’ characteristics, primary tumor, and SLN
features was proposed recently as a new scoring sys-
tem [non-sentinel node risk score (N-SNORE)] for pre-
diction of NSLN involvement [31]. This system
includes two of the pathological factors found by us
as independently related to the presence of NSLN
metastases: maximum size of the largest tumor de-
posit in SLN (although with different categorization
than according to Rotterdam criteria) and perinodal
lymphatic invasion of SLN (described by us as extra-
capsular extension). We suggest also that primary a
Breslow thickness >2 mm is independently related to
NSLN metastases, but we did not analyze the regres-
sion of a primary tumor as Wevers et al. did [31].
We are convinced that further studies (as the Mini-
tube trial organized by the EORTC Melanoma Group)
will establish the criteria used to limit of performance
of the unnecessary CLND [32], but currently, CLND
is still the standard of care in every case of positive
SLN biopsy.
Conclusions
Using a large comprehensive patient cohort with
long-term results, we have confirmed the crucial
Fig. 5 Overall survival curves according to extracapsular extension of
nodal metastases (0—no extracapsular extension, 1—extracapsular
extension) in group of patients with positive SLN biopsy after CLND
(cohort 2)
Fig. 6 Overall survival curves according to the presence of
metastases to non-sentinel lymph nodes (0—metastases to SLN
only, 1—metastases to SLN and NSLN) in group of patients with
positive SLN biopsy after CLND (cohort 2)
Fig. 7 Overall survival curves according to the size of metastases to
SLN according to Rotterdam criteria (SLN tumor size: 1, <0.1 mm; 2,
0.1–1.0 mm; 3, >1.0 mm) in group of patients with positive SLN
biopsy after CLND (cohort 2)
Table 5 Multivariate model—factors related to metastases to
non-sentinel nodes
Zmienna OR ORL ORU p value
Extracapsular metastases 2.022 0.939 4.352 0.072
Breslow thickness 1.102 1.042 1.166 0.001
Maximal diameter of metastatic deposit 1.068 1.013 1.126 0.015
Rutkowski et al. World Journal of Surgical Oncology  (2015) 13:299 Page 8 of 10
prognostic significance of SLN biopsy in cutaneous
melanoma. We have also identified factors related to
NSLN involvement, what may in the future limit indi-
cations for completion lymph node dissection in
selected patients, although prospective studies are ne-
cessary. SLN biopsy currently provides more import-
ant prognostic information than can be derived from
characteristics of the primary tumor only. For the pa-
tient with clinically node-negative disease, primary
tumor ulceration and mitotic rate are very important
factors in predicting the patient’s outcome. Nodal
metastases tumor burden influences the prognosis of
patients with positive SLN biopsy.
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